novo nordisk glp 1 agonist Ophthalmic Complications Observed After Use of GLP-1 Agonists Novo Nordisk signs deal for

Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62

or oral administration

Blue Cross and Blue Care Network came to this decision after careful consideration of GLP-1 weight loss drugs efficacy, safety and access and skyrocketing costs.

adults have obesity, with the rate increasing more than 10 percentage points in the past 2 decades

Compare 10 GLP-1 agonist medications for weight loss including semaglutide and tirzepatide

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing